Eventide Asset Management’s Applied Genetic Technologies Corporation AGTC Stock Holding History

Eventide Asset Management’s Portfolio AGTC Stock Details AGTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-184,100	Closed	-$1.27M	–	132
2017 Q1	$1.27M	Sell	184,100 -95,000	-34%	-$742K	0.08%	103
2016 Q4	$2.61M	Hold	279,100	–	–	0.17%	89
2016 Q3	$2.73M	Hold	279,100	–	–	0.17%	88
2016 Q2	$3.94M	Hold	279,100	–	–	0.24%	77
2016 Q1	$3.9M	Hold	279,100	–	–	0.22%	83
2015 Q4	$5.69M	Buy	279,100 +28,600	+11%	+$441K	0.28%	82
2015 Q3	$3.29M	Buy	250,500 +45,000	+22%	+$746K	0.19%	87
2015 Q2	$3.15M	Hold	205,500	–	–	0.17%	89
2015 Q1	$4.11M	Hold	205,500	–	–	0.31%	74
2014 Q4	$4.32M	Hold	205,500	–	–	0.47%	65
2014 Q3	$3.82M	Hold	205,500	–	–	0.53%	61
2014 Q2	$4.75M	Buy	+205,500	New	+$3.62M	0.65%	58

Other funds holding AGTC

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Eventide Asset Management's AGTC Position: Q2 2017 in Review

Eventide Asset Management sold out of Applied Genetic Technologies Corporation (AGTC) in Q2 2017, closing a stake of 184,100 shares — an estimated $1.27M sold.

Eventide Asset Management first reported a position in AGTC in Q2 2014 and held it in 12 quarters. The position peaked at $5.69M in Q4 2015. 77 funds tracked by Wall St. Rank hold AGTC as of Q2 2017.

Eventide Asset Management reported no remaining Applied Genetic Technologies Corporation position as of Q2 2017 after selling out during the quarter.
Eventide Asset Management sold 184,100 Applied Genetic Technologies Corporation shares in Q2 2017, an estimated $1.27M.
Eventide Asset Management first reported a position in Applied Genetic Technologies Corporation in Q2 2014 and held it in 12 quarters.
Eventide Asset Management's Applied Genetic Technologies Corporation position peaked at $5.69M in Q4 2015.
77 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q2 2017.

Based on Eventide Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.